Tune Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$182M
- Investors
-
14
Tune Therapeutics General Information
Description
Developer of an epigenetic programming platform designed to create new pathways for the treatment of disease. The company's platform helps to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases by tapping into the epigenome to program biology without altering the deoxyribonucleic acid sequence, enabling patients with treatments for pervasive diseases.
Contact Information
Website
www.tunetx.comCorporate Office
- 300 Morris Street
- Suite 320
- Durham, NC 27701
- United States
Corporate Office
- 300 Morris Street
- Suite 320
- Durham, NC 27701
- United States
Tune Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series B) | 12-Jan-2025 | $182M | Completed | Clinical Trials - Phase 1 | ||
| 1. Early Stage VC (Series A) | 02-Dec-2021 | Completed | Startup |
Tune Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A | 40,952,394 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 14.45% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Tune Therapeutics Comparisons
Industry
Financing
Details
Tune Therapeutics Competitors (2)
One of Tune Therapeutics’s 2 competitors is Fulcrum Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fulcrum Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Assembly Biosciences | Formerly VC-backed | South San Francisco, CA |
Tune Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tune Therapeutics Patents
Tune Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222119-A2 | Epi-editing fusion constructs for foxp3 activation | Pending | 15-Apr-2025 | ||
| WO-2026161895-A1 | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression | Pending | 27-Jan-2025 | ||
| WO-2026102058-A1 | Methods for treating chronic hepatitis b infection and related formulations | Pending | 06-Nov-2024 | ||
| WO-2026064753-A1 | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing | Pending | 23-Sep-2024 | ||
| WO-2026015647-A1 | Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1 | Pending | 09-Jul-2024 | C12N15/1138 |
Tune Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tune Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biovision Ventures | Venture Capital | Minority | ||
| Duke Capital Partners | Venture Capital | Minority | ||
| Hevolution Foundation | Corporation | Minority | ||
| Pappas Capital | Venture Capital | Minority | ||
| Regeneron Ventures | Corporate Venture Capital | Minority |
Tune Therapeutics FAQs
-
When was Tune Therapeutics founded?
Tune Therapeutics was founded in 2020.
-
Where is Tune Therapeutics headquartered?
Tune Therapeutics is headquartered in Durham, NC.
-
What is the size of Tune Therapeutics?
Tune Therapeutics has 50 total employees.
-
What industry is Tune Therapeutics in?
Tune Therapeutics’s primary industry is Biotechnology.
-
Is Tune Therapeutics a private or public company?
Tune Therapeutics is a Private company.
-
What is the current valuation of Tune Therapeutics?
The current valuation of Tune Therapeutics is .
-
What is Tune Therapeutics’s current revenue?
The current revenue for Tune Therapeutics is .
-
How much funding has Tune Therapeutics raised over time?
Tune Therapeutics has raised $222M.
-
Who are Tune Therapeutics’s investors?
Biovision Ventures, Duke Capital Partners, Hevolution Foundation, Pappas Capital, and Regeneron Ventures are 5 of 14 investors who have invested in Tune Therapeutics.
-
Who are Tune Therapeutics’s competitors?
Fulcrum Therapeutics and Assembly Biosciences are competitors of Tune Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
